Literature DB >> 31369109

Mechanisms and phenotypic consequences of acquisition of tigecycline resistance by Stenotrophomonas maltophilia.

Paula Blanco1, Fernando Corona1, José Luis Martinez1.   

Abstract

OBJECTIVES: To elucidate the potential mutation-driven mechanisms involved in the acquisition of tigecycline resistance by the opportunistic pathogen Stenotrophomonas maltophilia. The mutational trajectories and their effects on bacterial fitness, as well as cross-resistance and/or collateral susceptibility to other antibiotics, were also addressed.
METHODS: S. maltophilia populations were submitted to experimental evolution in the presence of increasing concentrations of tigecycline for 30 days. The genetic mechanisms involved in the acquisition of tigecycline resistance were determined by WGS. Resistance was evaluated by performing MIC assays. Fitness of the evolved populations and individual clones was assessed by measurement of the maximum growth rates.
RESULTS: All the tigecycline-evolved populations attained high-level resistance to tigecycline following different mutational trajectories, yet with some common elements. Among the mechanisms involved in low susceptibility to tigecycline, mutations in the SmeDEF efflux pump negative regulator smeT, changes in proteins involved in the biogenesis of the ribosome and modifications in the LPS biosynthesis pathway seem to play a major role. Besides tigecycline resistance, the evolved populations presented cross-resistance to other antibiotics, such as aztreonam and quinolones, and they were hypersusceptible to fosfomycin, suggesting a possible combination treatment. Further, we found that the selected resistance mechanisms impose a relevant fitness cost when bacteria grow in the absence of antibiotic.
CONCLUSIONS: Mutational resistance to tigecycline was easily selected during exposure to this antibiotic. However, the fitness cost may compromise the maintenance of S. maltophilia tigecycline-resistant populations in the absence of antibiotic.
© The Author(s) 2019. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Year:  2019        PMID: 31369109     DOI: 10.1093/jac/dkz326

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  7 in total

1.  Glucose-6-phosphate Reduces Fosfomycin Activity Against Stenotrophomonas maltophilia.

Authors:  Teresa Gil-Gil; José Luis Martínez
Journal:  Front Microbiol       Date:  2022-05-10       Impact factor: 6.064

2.  The Acquisition of Colistin Resistance Is Associated to the Amplification of a Large Chromosomal Region in Klebsiella pneumoniae kp52145.

Authors:  María Blanca Sánchez; Alicia Sánchez-Gorostiaga; Trinidad Cuesta; José Luis Martínez
Journal:  Int J Mol Sci       Date:  2021-01-11       Impact factor: 5.923

3.  The Contribution of Efflux Systems to Levofloxacin Resistance in Stenotrophomonas maltophilia Clinical Strains Isolated in Warsaw, Poland.

Authors:  Olga M Zając; Stefan Tyski; Agnieszka E Laudy
Journal:  Biology (Basel)       Date:  2022-07-12

4.  Advances in the Microbiology of Stenotrophomonas maltophilia.

Authors:  Joanna S Brooke
Journal:  Clin Microbiol Rev       Date:  2021-05-26       Impact factor: 50.129

5.  Antimicrobial Peptide Exposure Selects for Resistant and Fit Stenotrophomonas maltophilia Mutants That Show Cross-Resistance to Antibiotics.

Authors:  Paula Blanco; Karin Hjort; José L Martínez; Dan I Andersson
Journal:  mSphere       Date:  2020-09-30       Impact factor: 4.389

Review 6.  Antibiotic resistance: Time of synthesis in a post-genomic age.

Authors:  Teresa Gil-Gil; Luz Edith Ochoa-Sánchez; Fernando Baquero; José Luis Martínez
Journal:  Comput Struct Biotechnol J       Date:  2021-05-21       Impact factor: 7.271

7.  Fatal hemorrhagic pneumonia in patients with hematologic diseases and Stenotrophomonas maltophilia bacteremia: a retrospective study.

Authors:  Lixia Zhu; Lulu Wang; Yuping Zhang; Rongrong Chen; Xueying Li; Jianai Sun; Mingyu Zhu; Xiaolong Zheng; Li Li; Jingjing Zhu; Mixue Xie; Xiudi Yang; Wenjuan Yu; Hongyan Tong; Honghu Zhu; Wanzhuo Xie; Jie Jin; Xiujin Ye
Journal:  BMC Infect Dis       Date:  2021-07-31       Impact factor: 3.090

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.